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Introduction: Anemia of inflammation (AI) is a common complication of rheumatoid arthritis (RA) and has a
negative impact on RA symptoms and quality of life. Upregulation of hepcidin by inflammatory cytokines has been
implicated in AI. In this study, we evaluated and compared the effects of IL-6 and TNF-α blocking therapies on
anemia, disease activity, and iron-related parameters including serum hepcidin in RA patients.
Methods: Patients (n = 93) were treated with an anti-IL-6 receptor antibody (tocilizumab) or TNF-α inhibitors for 16
weeks. Major disease activity indicators and iron-related parameters including serum hepcidin-25 were monitored
before and 2, 4, 8, and 16 weeks after the initiation of treatment. Effects of tocilizumab and infliximab (anti-TNF-α
antibody) on cytokine-induced hepcidin expression in hepatoma cells were analyzed by quantitative real-time PCR.
Results: Anemia at base line was present in 66% of patients. Baseline serum hepcidin-25 levels were correlated
positively with serum ferritin, C-reactive protein (CRP), vascular endothelial growth factor (VEGF) levels and Disease
Activity Score 28 (DAS28). Significant improvements in anemia and disease activity, and reductions in serum
hepcidin-25 levels were observed within 2 weeks in both groups, and these effects were more pronounced in the
tocilizumab group than in the TNF-α inhibitors group. Serum hepcidin-25 reduction by the TNF-α inhibitor therapy
was accompanied by a decrease in serum IL-6, suggesting that the effect of TNF-α on the induction of hepcidin-25
was indirect. In in vitro experiments, stimulation with the cytokine combination of IL-6+TNF-α induced weaker
hepcidin expression than did with IL-6 alone, and this induction was completely suppressed by tocilizumab but not
by infliximab.
Conclusions: Hepcidin-mediated iron metabolism may contribute to the pathogenesis of RA-related anemia. In our
cohort, tocilizumab was more effective than TNF-α inhibitors for improving anemia and normalizing iron
metabolism in RA patients by inhibiting hepcidin production.* Correspondence: kyoshi@chem.eng.osaka-u.ac.jp
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Rheumatoid arthritis (RA) is a chronic inflammatory auto-
immune disease characterized by persistent synovitis and
progressive destruction of cartilage and bones in multiple
joints [1], and its most common extra-articular manifest-
ation is anemia. Most cases of RA-associated anemia (RA-
anemia) are characterized as anemia of inflammation (AI),
also known as anemia of chronic disease. There is evi-
dence, however, that RA patients with anemia have a more
severe form of the disease and more serious joint damage
[2-4]. Proinflammatory cytokines, particularly tumor ne-
crosis factor α (TNF-α), interleukin 6 (IL-6) and IL-1 play
important roles in the pathogenesis of RA and are thought
to contribute to the development of RA-anemia by modu-
lating iron metabolism and suppressing bone marrow
erythropoiesis [5-7]. Treatments with anticytokine agents
such as infliximab (anti-TNF-α), tocilizumab (anti-IL-6
receptor) and anakinra (anti-IL-1) have been shown to ef-
fectively ameliorate disease activity, inhibit joint destruc-
tion and significantly increase serum hemoglobin (Hb)
levels in RA patients [8-13]. These findings suggest that
the aforementioned biologic inhibitors have an antianemic
effect as well as antirheumatic activities. However, the
exact etiology of RA-anemia remains unclear.
Hepcidin is an antimicrobial peptide hormone synthe-
sized mainly in the liver which has emerged as a key regu-
lator of body iron homeostasis [14,15]. It reduces intestinal
iron absorption and blocks iron release from body stores
by downregulating expression of ferroportin, which is an
iron exporter expressed on the surface of enterocytes and
macrophages [16]. This hormone is modulated by iron
homeostasis, hypoxia, erythropoiesis and inflammatory
stimuli [17,18]. IL-6 is a major inducer of hepcidin expres-
sion during inflammation, and an increase in hepcidin syn-
thesis is implicated in the etiology of AI [19,20].
We previously demonstrated that treatment with
tocilizumab, by inhibiting hepcidin production, can reduce
serum hepcidin and improve AI in patients with
multicentric Castleman’s disease (MCD), a rare, IL-6-me-
diated lymphoproliferative disorder [21]. In contrast, TNF-
α does not induce, but rather inhibits, hepcidin expression
in vitro [22]. Because various cytokines are overproduced
under inflammatory conditions, the control of hepcidin
production in RA can be expected to be very complex.
Though recent studies have found that an increase in
serum hepcidin in active RA patients was associated with
elevated serum IL-6 and TNF-α levels [23,24], the role of
hepcidin and its regulation by cytokines in the pathogen-
esis of RA-anemia is still largely unknown.
To clarify these points, we evaluated and compared
the effects of tocilizumab and TNF-α inhibitors on
serum hepcidin levels, hematological parameters, iron
status and disease activity before and after the initiation
of these therapies for RA patients.Methods
Patients and clinical laboratory examinations
Participants were recruited from the RA Outpatient
Unit at Higashihiroshima Memorial Hospital. Patients
were considered eligible if they fulfilled the American
Rheumatism Association revised criteria for classification
of RA [25] and their disease duration was longer than six
months. Patients who had received erythropoiesis-
stimulating agents (ESAs) or iron (oral or intravenous)
during the two months prior to the initiation of this study
were excluded. The eligible patients who had responded
insufficiently to treatment with at least one disease-
modifying antirheumatic drug (DMARD) or immu-
nosuppressant were recommended for treatment with
tocilizumab or TNF-α inhibitors by their attending physi-
cians. The choice of treatment was made at the discretion
of these attending physicians. From among eligible pa-
tients who started tocilizumab or TNF-α inhibitor therapy
after June 2008, 50 consecutive patients in each treatment
group were enrolled. Four patients in the tocilizumab
group and three in the TNF-α inhibitor group dropped
out of the study because of severe infection or for personal
reasons. As a result, a total of 93 patients comprising 46
tocilizumab users and 47 TNF-α inhibitor users were ana-
lyzed in this study. The TNF-α inhibitor users were initi-
ated on treatment with any of three inhibitors (etanercept,
n = 22; infliximab, n = 14; or adalimumab, n = 11),
together with oral methotrexate at a standard dose, unless
the rheumatologist decided otherwise. Tocilizumab was
infused in principle every four weeks at a dose of 8 mg/kg,
a rate based on our previous dose determination studies
[26]. Blood samples were obtained before treatment and 2,
4, 8 and 16 weeks after the initiation of treatment and
then separated by centrifugation at 3,000 rpm and stored
at −80°C until assayed.
Serum hepcidin-25 in all RA patients and in 16 healthy
volunteers was quantified using a liquid chromatography-
tandem mass spectrometry-based assay system as reported
previously [21]. IL-6, TNF-α and vascular endothelial
growth factor (VEGF) were measured using the Bio-Plex
Suspension Array System (Bio-Rad Laboratories, Tokyo,
Japan). Serum hematological parameters were measured
using standard laboratory techniques. Disease Activity
Score in 28 joints (DAS28) [27], used to assess patient
reported outcome, was measured at baseline and at 16
weeks. This study was approved by the ethics committee
of Higashihiroshima Memorial Hospital, and informed
consent was obtained from all patients.
Reagents and cell culture
Recombinant human IL-6 was provided by Ajinomoto
(Kawasaki, Japan), and recombinant human TNF-α and
IL-1β were purchased from Invitrogen (Carlsbad, CA,
USA). Humanized anti-IL-6 receptor antibody (anti-IL6R
Table 1 Baseline clinical characteristics of patientsa
Characteristics TCZ users (N = 46) TNFi users (N = 47)
Age (years) 60 (28 to 75) 55 (30 to 76)
Gender 3 males, 43 females 9 males, 38 females
Hb (g/dl) 11.4 (8.9 to 14.4) 11.8 (7.7 to 15.3)
MCV (fl) 91.7 (72.4 to 101.5) 94.2 (79.3 to 104.1)
Ferritin (ng/ml) 81.4 (13.5 to 285.3) 99.2 (9.8 to 398.2)
Fe (μg/dl) 45.8 (9.0 to 120.0) 56.5 (10.0 to 138.0)
CRP (mg/dl) 3.37 (0.05 to 15.24) 2.11 (0.04 to 9.16)
Hepcidin-25 (ng/ml) 28.6 (0.3 to 123) 30.5 (0.4 to 127.4)
Duration of RA (years) 12.54 (1.6 to 43) 8.16 (0.8 to 28)
SJC 7.24 (0 to 24) 5.59 (0 to 23)
TJC 6.74 (0 to 23) 6.54 (1 to 23)
RF (IU/ml) 165.54 (0 to 1,166) 144.24 (0 to 1,625)
DAS28 4.74 (2.00to 7.39) 4.45 (2.33 to 7.23)
aCRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; Fe, serum
iron; ferritin, serum ferritin; Hb, hemoglobin; MCV, mean corpuscular volume;
RF, rheumatoid factor; SJC, swollen joint count; TCZ, tocilizumab; TJC, tender
joint count; TNFi, tumor necrosis factor α inhibitor. All data are means (ranges)
unless otherwise specified.
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Pharmaceutical Co Ltd (Tokyo, Japan), and anti-TNF-α
Ab (infliximab) was provided by Mitsubishi-Tanabe
Pharmaceutical Co Ltd (Tokyo, Japan). The human
hepatoma cell lines PLC/PRF/5 and Hep3B were donated
by Tohoku University (Sendai, Japan) and were grown in
Dulbecco’s modified Eagle’s medium supplemented with
10% heat-inactivated fetal bovine serum (FBS) and 50 U/ml
penicillin-streptomycin. The monocyte cell line U937
(American Type Culture Collection, Manassas, VA,
USA) was cultured in RPMI 1640 medium containing
10% heat-inactivated FBS, 100 U/ml penicillin and 100
μg/ml streptomycin.
RNA preparation and real-time RT-PCR
Cells were seeded at 5 × 105 cells/well in six-well plates
and stimulated with IL-6 (10 ng/ml), TNF-α (10 ng/ml)
and IL-1β (10 ng/ml) under subconfluent conditions. The
effect of IL-6 or TNF-α blockage was investigated by
means of preincubation for 30 minutes with tocilizumab
(25 μg/ml) or infliximab (25 μg/ml). To test the effect of
TNF-α on IL-6 and ferroportin expression in monocytic
cells, U937 cells were treated with 0.01 to 10 ng/ml re-
combinant TNF-α for six hours. To test the effect of TNF-
α on IL-6-induced hepcidin expression in hepatocytic
cells, PLC/PRF/5 and Hep3B cells were incubated with
0.01 to 10 ng/ml recombinant TNF-α for 30 minutes and
then treated with IL-6. After six hours of TNF-α or IL-6
treatment, total RNA was extracted with the RNeasy Mini
Kit (Qiagen GmbH, Hilden, Germany) according to the
manufacturer’s instructions. cDNA was then synthesized
with Moloney murine leukemia virus reverse transcriptase
(Promega, Madison, WI, USA) in 25-μl reactions contai-
ning 2 μg of total RNA. Real-time quantitative RT-PCR
was performed with the GeneAmp 7000 Sequence Detec-
tion System and SYBR Green dye (Applied Biosystems,
Foster City, CA, USA) according to the manufacturer’s
protocol. The following PCR primers were used for am-
plifying human hepcidin cDNA: forward primer, 5′-
CCTGACCAGTGGCTCTGTTT-3′, and reverse primer,
5′CACATCCCACACTTTGATCG-3′; for amplifying hu-
man IL-6 cDNA: forward primer, 5′-ATTCGGTACAT
CCTCGACGGCA-3′, and reverse primer, 5′-CAGCCA
TCTTTGGAAGGTTCAGGT-3′; and for amplifying hu-
man ferroportin cDNA: forward primer, 5′-CCCGGAG
ACAAGTCCTGAATC-3′, and reverse primer, 5′-TGG
CCCATTGCCACAAAGGAG-3′. The PCR was perfor-
med for a final volume of 50 μl comprising 2 × 25 μl SYBR
Green PCR Master Mix (Applied Biosystems). Thermal
cycle parameters were 2 minutes at 50°C and 10 minutes
at 95°C, followed by 40 cycles of amplification with 15 sec-
onds at 95°C for denaturation and 1 minute at 60°C for
annealing and elongation. β2 microglobulin was used as an
internal control for correction of hepcidin expression.Experiments were performed in triplicate, and each was
repeated three times with consistent results.
Statistical analysis
The overall effect of treatment was evaluated with the
paired t-test on the basis of changes from baseline level
observed at different intervals following tocilizumab
and TNF-α inhibitor administration. Group compari-
sons were performed with Pearson’s correlation test.
The values of serum hepcidin-25, ferritin and VEGF were
log-transformed to normalize the distribution before cor-
relation analyses. Data are expressed as means ± SD or
SEM as indicated in the figure legends. P < 0.05 was con-
sidered significant.
Results
Characteristics of the study population
According to the World Health Organization definition
of anemia (Hb levels lower than 13.0 g/dl for men and
below 12.0 g/dl for women), 61 (66%) of the 93 active
RA patients who participated in this study were anemic.
Most of them showed mild anemia with a mean Hb con-
centration of 11.3 g/dl. The clinical characteristics of the
two patient groups treated with either tocilizumab (46
cases) or TNF-α inhibitors (47 cases) are summarized in
Table 1. There were no significant differences (P > 0.05)
between the two groups for the examined variables, al-
though the mean values for age, disease duration and
CRP were slightly higher for the tocilizumab group than
for the TNF-α inhibitor group. The mean level of serum
hepcidin-25 in all the patients was higher (29.6 ng/ml)
than that in healthy controls (20.0 ± 12.0 ng/ml), though
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line showed an inverse association with CRP (r = −0.45,
P < 0.001) and DAS28 (r = −0.21, P = 0.04). The mean
levels of serum ferritin and mean corpuscular volume
(MCV) in all patients were normal (ferritin: 90.3 ng/ml;
MCV: 93 fl), but the actual values varied widely, indicating
that anemia in some cases might have originated not only
from inflammation but also from other factors, including
iron deficiency, folate deficiency and drug effects.
Associations of serum hepcidin with hematologic
parameters, iron status and rheumatoid arthritis activity
Serum hepcidin-25 levels and the various parameters at
baseline for all the patients were analyzed for possible asso-
ciations. Significant and positive correlations of serum
hepcidin-25 levels were found with serum ferritin (r = 0.67,
P < 0.001), CRP (r = 0.36, P < 0.001) and VEGF (r = 0.30,
P < 0.001) levels, as well as with the DAS28 score (r = 0.28,
P < 0.001) (Figures 1A to 1D). In contrast, serum hepcidin-
25 levels did not show any significant correlation with the
levels of serum IL-6 (r = 0.15, P = 0.15) or TNF-α (r = 0.09,
P = 0.37) or Hb (r = 0.006, P = 0.99). The most significant
correlation was observed between serum hepcidin-25 and
ferritin levels (r = 0.67) at the beginning of these treat-
ments, and this strong and significant correlation lasted
throughout the 16-week observation period (Figure 2).Figure 1 Correlation of serum hepcidin 25 levels with serum ferritin,
activity score in 28 joints in rheumatoid arthritis patients. Baseline val
and (A) ferritin, (B) C-reactive protein (CRP), (C) vascular endothelial growthEffects of treatments with tocilizumab and tumor necrosis
factor α inhibitors on serum hepcidin-25 levels
The average levels of serum hepcidin-25 before treat-
ment between the tocilizumab and the TNF-α inhibitor
groups were comparable (Table 1). Treatment with
tocilizumab or TNF-α inhibitors resulted in a dramatic
decrease in serum hepcidin-25 levels within two weeks,
and this inhibition lasted throughout the sixteen-week
observation period (P < 0.01 vs. baseline) (Figure 3A).
The reductions in serum hepcidin-25 levels were 82%,
62%, 80% and 86% at two, four, eight and sixteen weeks,
respectively, for the tocilizumab treatment group, and
56%, 39%, 55% and 50% at two, four, eight and sixteen
weeks, respectively, for the TNF-α inhibitor treatment
group. Tocilizumab thus displayed a significantly stron-
ger effect than the TNF-α inhibitors on suppressing
serum hepcidin-25 levels after the initiation of these
treatments (P < 0.01) throughout the observation period
(Figure 3A).
Effects of tocilizumab and tumor necrosis factor α inhibitor
treatments on hematological and iron-related parameters
The mean values of Hb, serum iron (Fe), ferritin and
MCV before treatment were comparable between the
tocilizumab and the TNF-α inhibitor groups. Both
tocilizumab and TNF-α inhibitor therapies continuallyC-reactive protein, vascular endothelial growth factor and disease
ues showed a significant correlation between hepcidin-25 (Hepc-25)
factor (VEGF) and (D) Disease Activity Score in 28 joints (DAS28).
Figure 2 Correlation between serum hepcidin-25 and ferritin at observation time points after biologic drug treatment. Significant
correlations were observed at (A) baseline, (B) two weeks, (C) four weeks and (D) sixteen weeks. Hepc-25, hepcidin 25.
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of the study period, mean Hb values had increased from
11.4 to 12.8 g/dl (P < 0.01) in the tocilizumab group and
from 11.8 to 12.5 g/dl (P < 0.01) in the TNF-α inhibitor
group (Figure 3B). The mean Hb increase was 1.4 g/dlFigure 3 Comparison of the effects of tocilizumab and tumor necrosi
rheumatoid arthritis. Treatment effects were assessed at two, four, eight
hepcidin-25 was quantified using a liquid chromatography-tandem mass sp
using standard laboratory techniques. (A) Serum levels of hepcidin-25 (Hep
(Ferritin). TCZ, tocilizumab; TNFi, tumor necrosis factor α inhibitors. Values a
by paired t-test comparing changes from baseline between the two groupin the tocilizumab group, which was significantly larger
than that for the TNF-α inhibitor group (0.7 g/dl) (P <
0.01), indicating that tocilizumab had a more beneficial
effect than TNF-α inhibitors on improvement of RA-
anemia. Fe gradually increased, and serum ferritin levelss factor α inhibitors on hepcidin-25 and anemia-related factors in
and sixteen weeks after the start of biologic drug therapy. Serum
ectrometry-based assay system, and other parameters were measured
c-25), (B) hemoglobin (Hb), (C) serum iron (Fe) and (D) serum ferritin
re the means and SEM. *P < 0.01 vs. baseline by paired t-test. #P < 0.01
s at 16 weeks. NS, not significant.
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observation period in both treatment groups (Figures 3C
and 3D). By the end of the study period, the mean Fe
value had increased from 45.8 to 83.7 μg/dl (P < 0.01) in
the tocilizumab group and from 56.5 to 80.4 μg/dl (P <
0.01) in the TNF-α inhibitor group (Figure 3C). By the
end of the study period, the mean ferritin value had de-
creased from 81.4 to 33.9 ng/ml (P < 0.01) in the
tocilizumab group and from 94.2 to 50.8 ng/ml (P < 0.01)
in the TNF-α inhibitor group (Figure 3D). By the end of
the study period, the mean MCV value had increased
from 91.7 to 93.0 fl (P < 0.05) in the tocilizumab group ,
but the change in mean MCV value was not significant in
the TNF-α inhibitor group (from 94.2 to 94.8 fl; P > 0.05).
Effects of tocilizumab and tumor necrosis factor α inhibitor
treatments on rheumatoid arthritis disease activity
The initial serum levels of CRP and VEGF tended to be el-
evated in our patients before the anticytokine treatments.
We found mean CRP levels of 3.37 and 2.21 mg/dl (refer-
ence range, <0.2 mg/dl) and mean VEGF levels of 286 and
273 pg/ml (reference range, 8.4 to 238.7 pg/ml) for the
tocilizumab and TNF-α inhibitor groups, respectively.
After the initiation of treatment in the tocilizumab and
TNF-α inhibitor groups, mean serum CRP levels de-
creased to 0.08 mg/dl and 0.58 mg/dl and mean serumFigure 4 Comparison of effects of tocilizumab and tumor necrosis fac
16-week treatment. (A) C-reactive protein (CRP). (B) Vascular endothelial
tender joint count (TJC), Visual Analogue Scale (VAS) score and rheumatoid
Values are means and SEM. *P < 0.01, vs. baseline by paired t-test. #P < 0.01
baseline between the two groups at 16 weeks.VEGF levels decreased to 158 pg/ml and 201 pg/ml, re-
spectively (P < 0.01) (Figures 4A and 4B). All these effects
continued until 16 weeks, with average values of 0.11 mg/
dl for CRP and 88 pg/ml for VEGF in the tocilizumab
group and average values of 0.39 mg/dl for CRP and 167
pg/ml for VEGF in the TNF-α inhibitor group (Figures 4A
and 4B). At the end of the study period, both serum CRP
and VEGF levels were significantly lower in the
tocilizumab than in the TNF-α inhibitor group (P < 0.01
for CRP and VEGF).
Both tocilizumab and TNF-α inhibitor treatments also
resulted in significant reductions in DAS28, Visual
Analogue Scale score, tender joint count and rheuma-
toid factor values (Figure 4C) at 16 weeks. Although
tocilizumab was more effective than TNF-α inhibitors
for reducing DAS28 (P < 0.05), the efficacy for the other
indicators was similar between these two groups.
Interactive effects of cytokine combination on hepcidin
expression in vitro
We found that treatment of RA patients with TNF-α in-
hibitors reduced serum hepcidin-25 (Figure 3A). Because
IL-6 is a major inducer of hepcidin production during
inflammation, we hypothesized that the reduction in
serum hepcidin-25 levels in the TNF-α inhibitor users
might have been the result of the decline in serum IL-6tor α inhibitors on rheumatoid arthritis disease activity during
growth factor (VEGF). (C) Disease Activity Score in 28 joints (DAS28),
factor (RF). TCZ, tocilizumab; TNFi, tumor necrosis factor α inhibitors.
and $P < 0.05 by paired t-test for comparison of changes from
Song et al. Arthritis Research & Therapy 2013, 15:R141 Page 7 of 10
http://arthritis-research.com/content/15/5/R141levels. In fact, serum IL-6 levels in the TNF-α inhibitor
users declined throughout the study period (Figure 5A),
thus providing evidence in support of our hypothesis.
To further assess the roles of TNF-α and IL-1β in the
pathogenesis of RA-anemia and their effects on IL-6-in-
duced hepcidin mRNA expression, we performed in vitro
real-time RT-PCR assays using a hepatoma-derived cell
line. As shown in Figure 5B, the basal hepcidin mRNA
levels increased by a factor of up to 12.4 at six hours after
the addition of IL-6 to PLC/PRF/5 cells. TNF-α (10 ng/ml)
reduced hepcidin mRNA levels by approximately 60%
compared with the effect of the nonstimulated control
group (Figure 5B). The hepcidin mRNA level induced by
IL-6 together with TNF-α was approximately 40% lower
than that induced by IL-6 alone. Similarly, the hepcidin
expression level induced by IL-6 together with IL-1β was
30% lower than that induced by IL-6 alone. Hepcidin
levels induced by the triple combination of IL-6, TNF-α
and IL-1β were even lower than those induced by the
double combination of IL-6 and TNF-α (Figure 5B). Simi-
lar results were observed in the Hep3B cell line (data not
shown).Figure 5 Tumor necrosis factor α inhibitor treatment indirectly reduc
reducing interleukin 6 levels. (A) Significant reductions in mean serum in
sixteen weeks after treatment with tumor necrosis factor α (TNFα) inhibitor
(IFX; 25 μg/ml) on hepcidin mRNA expression induced by IL-6 (10 ng/ml), T
cells. Hepcidin mRNA was assayed by quantitative real-time PCR six hours a
stimulation was determined in U937 cells grown in medium containing TN
increased in a dose-dependent manner. (D) Ferroportin mRNA expression
medium containing TNFα at final concentrations of 0.1, 1, 10 and 50 ng/m
data represent means ± SD of triplicate measurements. The same experime
representative data are shown. *P < 0.01 by paired t-test.In addition, we evaluated the effect of IL-6 and TNF-α
blockade on hepcidin mRNA expression by treating
PLC/PRF/5 cells with tocilizumab (25 μg/ml) and infli-
ximab (25 μg/ml) in the presence of IL-6 (10 ng/ml) to-
gether with TNF-α (10 ng/ml) and IL-1β (10 ng/ml).
Tocilizumab treatment eliminated the combined effect
of IL-6, TNF-α and IL-1β, so that the hepcidin expres-
sion level returned to the baseline (Figure 5B). In con-
trast, hepcidin expression remained elevated by the
infliximab treatment (Figure 5B). We next assessed the
effects of TNF-α on the mRNA expression of IL-6 and
ferroportin in monocytic U937 cells. IL-6 mRNA levels
were significantly upregulated, and ferroportin mRNA
levels were significantly downregulated, by TNF-α in a
dose-dependent manner (Figures 5C and 5D).
Discussion
Before treatment with various biologic drugs, serum
hepcidin-25 level in RA patients showed a significant
positive correlation with serum ferritin, CRP and VEGF
levels as well as DAS28 score. These correlations suggest
that there is a link between hepcidin, abnormal irones hepcidin production in rheumatoid arthritis patients by
terleukin 6 (IL-6) concentrations were observed at two, four and
s. (B) Effects of tocilizumab (TCZ; 25 μg/ml) and infliximab
NFα (10 ng/ml), IL-1β (10 ng/ml) and their combinations in PLC/PRF/5
fter the stimulation. (C) IL-6 mRNA expression response to TNFα
Fα at final concentrations of 0.1, 1, 10 and 50 ng/ml. IL-6 expression
response to TNFα stimulation was determined in U937 cells grown in
l. Ferroportin expression decreased in a dose-dependent manner. The
nt was repeated at least three times with consistent results, and
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correlation between the serum hepcidin level and serum
IL-6 level was unexpectedly not significant. This was
probably due to the presence of confounding regulatory
factors of hepcidin production, such as anemia and iron
deficiency. We found that blocking the IL-6 or TNF-α
pathway with tocilizumab or TNF-α inhibitors, respect-
ively, significantly reduced serum hepcidin-25 levels and
improved anemia and disease activity in RA patients, in-
dicating that these cytokines are involved in both
hepcidin production and the pathogenesis of RA-
anemia. It is also worth noting that stronger inhibition
of hepcidin-25 and significantly greater improvement in
RA-anemia were observed in patients treated with
tocilizumab than in patients treated with TNF-α inhibi-
tors throughout the observation period.
Previously, we demonstrated that tocilizumab com-
pletely blocked IL-6-induced hepcidin expression in
hepatoma-derived cell lines, and it effectively improved
AI by inhibiting hepcidin production in MCD patients
[21]. Presumably, tocilizumab plays the same role in RA-
anemia. However, the mechanisms how anti-TNF-α in-
hibitors can improve RA-anemia is largely unknown.
Unlike in MCD, multiple cytokines such as IL-6, TNF-α
and IL-1 are involved in the pathogenesis of RA-anemia,
and we therefore analyzed the effects of cytokine combi-
nations on hepcidin production in hepatoma cells. As
seen in Figure 5B, tocilizumab, but not infliximab, com-
pletely blocked hepcidin mRNA expression induced by
the combination of IL-6+TNF-α+IL-1. We also found
that TNF-α inhibited both basal level and IL-6-induced
hepcidin expressions in hepatoma cells. Interestingly,
however, TNF-α induced IL-6 mRNA expression in
monocytic U937 cells in vitro. These results, taken to-
gether with the clinical finding that IL-6 levels were re-
duced in RA patients treated with TNF-α inhibitors,
suggest that the inhibition of serum hepcidin-25 levels
by TNF-α inhibitors in RA patients may be caused indir-
ectly by a reduction in IL-6 production. These results
make it clear that IL-6 is mainly responsible for hepcidin
production in RA-anemia patients, which explains why
tocilizumab is superior to TNF-α inhibitors for suppres-
sion of hepcidin production in RA.
However, it should be remembered that the pathogen-
esis of RA-anemia is complex and multifactorial. Al-
though AI, mainly mediated by the IL-6–hepcidin axis,
is considered the most frequent cause of anemia in RA,
iron deficiency anemia (IDA), sometimes caused by
gastrointestinal blood loss associated with the use of
non-steroidal anti-inflammatory drugs, has been esti-
mated to be the second most common form of anemia
in RA. In fact, some of our patients showed relatively
low serum hepcidin and ferritin levels and the anemia
of such patients may be mainly attributable to irondeficiency. Therefore, hepcidin is not the only molecule
playing part in bringing about this condition. It has
been reported and confirmed by us that TNF-α can in-
hibit ferroportin mRNA expression in vitro and in vivo
[28]. Ferroportin is the only cellular iron exporter in
mammalian cells. In fact, TNF-α may also play an im-
portant role in RA-anemia via hepcidin-independent
pathways as reported previously [12]. Another possible
mechanism is that the reduction in serum hepcidin may
be the result of feedback from amelioration of inflam-
mation after treatment with TNF-α inhibitors.
Therapies using tocilizumab and TNF-α inhibitors
both resulted not only in a reduction of serum hepcidin-
25 levels, but also progressively normalized iron-related
parameters such as serum Fe and Ferritin levels. Ferritin
is a cellular storage protein for iron and elevated ferritin
levels generally reflect excessive iron storage as com-
monly observed in AI. Serum ferritin levels in our RA
patients before the treatment showed a significant correl-
ation with serum hepcidin-25 levels, indicating an associ-
ation between hepcidin and iron accumulation under RA
conditions. It can thus be speculated that excessive hep-
cidin leads to an increase in iron storage and reduces the
amount of serum iron available for Hb synthesis and
erythrocyte production, which leads in turn to anemia in
RA. Since the initiation of tocilizumab and TNF-α inhibi-
tor treatments resulted in down-regulation of both serum
hepcidin and ferritin levels, and since a strong correlation
between serum hepcidin and ferritin was observed
throughout the treatment period, it is speculated that im-
provement in anemia was generated by improved iron
utilization through hepcidin downregulation.
Angiogenesis in synovial membranes, which is mainly
regulated by VEGF, is a characteristic feature of RA pa-
tients. There is a great deal of evidence suggesting that
VEGF plays an important role in the pathogenesis of RA
[29]. Serum VEGF levels in RA patients correlate with
disease activity scores and radiologically determined pro-
gression state [30]. Furthermore, both IL-6 and TNF-α
can induce VEGF production [29,30] and anemia report-
edly impacts angiogenesis via impairment of tissue oxy-
genation, because hypoxia is a major stimulus for the
up-regulation of VEGF. Our results showed that serum
hepcidin levels correlated with the serum VEGF levels in
RA, suggesting that hepcidin-induced anemia can stimu-
late angiogenesis. We previously demonstrated that
treatment with tocilizumab significantly reduces VEGF
in RA [29], and in the study reported here, we confirmed
that tocilizumab is more effective than TNF-α inhibitors
for reducing serum VEGF.
Our finding that TNF-α inhibits both the basal level
and IL-6-induced hepcidin expression in hepatocytic cell
lines is consistent with that of a previous report [22]. In
addition, in another preliminary study cohort comparing
Song et al. Arthritis Research & Therapy 2013, 15:R141 Page 9 of 10
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that RA patients showed significantly higher serum
TNF-α and lower serum hepcidin-25 concentrations
than did MCD patients (data not shown), although the
two patient groups showed comparably elevated values
for IL-6. Most recently, Shanmugam et al. [31] demon-
strated that TNF-α had a negative regulatory effect on
hepcidin in a mouse model of innate colitis. Therefore,
our results and those of other studies suggest that TNF-
α counteracts the effect of IL-6 on hepcidin production
and support the notion that TNF-α may play a negative
role in hepcidin production. Thus, the relatively low
serum hepcidin-25 levels in patients with RA-anemia
may partially be due to a balance between opposing ef-
fects of hepcidin-regulating cytokines such as IL-6 and
TNF-α. However, it is also quite possible that iron defi-
ciency and other negative regulators are involved in the
downregulation of serum hepcidin levels in AI as we
previously reported [21].Conclusions
To the best of our knowledge, this investigation is the first
to compare the effects of tocilizumab and anti-TNF-α bio-
logic drugs on RA-anemia based on changes in serum
hepcidin levels. The results of our study suggest that
tocilizumab is superior to TNF-α inhibitors at improving
the hematologic, iron-related and inflammatory parame-
ters in RA patients and therefore should be particularly ef-
fective for patients with severe RA-anemia.
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